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o We Really
nderstand Pimecrolimus?*
arc Vorpahl, MD,† Aloke V. Finn, MD,‡
asataka Nakano, MD,† Renu Virmani, MD†
aithersburg, Maryland; and Atlanta, Georgia
imecrolimus was specifically developed for the topical
reatment of inflammatory skin diseases. Like tacrolimus, it
inds to the cytosolic receptor FK506 binding protein
Macrophilin-12). This complex inhibits the calcium-
ependent phosphatase calcineurin and the translocation of
he nuclear factor of activated T-cells transcription factor
NF-AT), which leads to an inhibition of inflammatory
ytokines in T cells and mast cells. Pimecrolimus does not
irectly affect cell cycle regulation and therefore does have
istinct differences from sirolimus or its analogue everoli-
us, zotarolimus, or biolimus A9, the most commonly used
gents used in drug-eluting stents. The antirestenotic effi-
acy of mammalian target of rapamycin (mTOR) inhibition
y sirolimus is based in part on its ability to prevent the
egradation of p27Kip1, a cyclin-dependent kinase inhibitor
hat plays an important role in smooth muscle cell (SMC)
roliferation and migration. The use of pimecrolimus as an
ntirestenotic agent then relies on targeting inflammation
ather than cell proliferation.
See page 1017
In this issue of JACC: Cardiovascular Interventions, Orm-
ston et al. (1) present results from clinical and preclinical
tudies of pimecrolimus-eluting stents. Pimecrolimus was
prayed in a solvent at a dose of 400 mg/stent, and a
op-coat of paralene C was applied to the stent. The results
f the phase I clinical trial performed in noncomplex lesions
howed an unexpectedly high in-stent binary restenosis
54%), with greater in-stent late loss (1.44 mm) in the
imecrolimus-eluting stent in relation to bare-metal stent
BMS) historical controls (0.91 mm) p  0.03. Preclinical
tudies carried out in a porcine model failed to predict this
xcessive neointimal growth.
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the †CVPath Institute, Inc., Gaithersburg, Maryland; and ‡Emory Univer-u
ity, Atlanta, Georgia. For full author disclosures, please see the end of this Editorial
omment.On first glance, the reasons for the failure of the preclin-
cal studies to foreshadow these results are puzzling and
aise questions about the reliability of preclinical models for
redicting outcomes in humans. However, a closer exami-
ation of these results reveals some important insights. It is
lear the results actually might have been misinterpreted by
he authors. In fact, these studies showed safety but not
fficacy of the pimecrolimus stent system. The artery size
as significantly smaller (p  0.04) in the group with
00-g pimecrolimus and polymer than in all other groups.
his flaw in the study design would tend to favor less
eointimal area in the experimental arms compared with
ontrol. Therefore, the borderline significant reduction in
eointimal area measurement (p  0.06) might be a result
f size differences rather than of drug efficacy. This is
einforced by the fact that the percent stenosis, a measure-
ent that is independent of vessel size, was not significantly
ess in the pimecrolimus arm, despite the fact that there was
definite trend toward less stenosis (25  6% vs. 34  0%
or BMS, and 30  12% for polymer only), with injury and
nflammatory scores being uniformly low in all groups. In
ddition, the 90-day study failed to raise any concern that
o excessive neointimal formation or inflammation was
bserved. Further supporting our contention about the lack
f efficacy is the finding that the neointima in the treated
rm relative to control did not show delayed healing or even
decrease in inflammation, which would have suggested a
iological effect of the drug.
The preclinical study also failed to raise any concern that
here might be an increase in the neointimal formation that
ould lead to greater restenosis. However, we are not given
he basic information regarding the release kinetics of the
rug, the tissue concentration in the arterial wall, or the
olvent used to dissolve the drug, all essential pieces of
nformation for estimating its potential efficacy.
Given the lack of efficacy seen in both the preclinical
odel and humans, the question arises why calcineurin
nhibitors might not be the optimal drugs for local drug
elivery on a stent in human coronary arteries? In light of
hese data, the concept of modulating the inflammatory
esponse to reduce restenosis needs to be re-examined. In
uman and animal models it has been suggested that
nflammation plays an important role in in-stent neointimal
rowth and restenosis (2–4). In stented rabbit arteries early
eutrophil infiltration is followed by prolonged macrophage
nfiltration and interleukin (IL)-8 and monocyte chemotac-
ic protein 1 levels remain high beyond the 14-day period.
lockage of early monocyte recruitment with anti-
nflammatory agents has been shown in animal models to
esult in reduction in neointimal formation. This study also
emonstrated a linear relationship between tissue macro-
hage content and neointimal area (3). Until recently the
ole of T-cell in the proliferation of intimal cells was
nknown. Evidence has emerged suggesting that recruit-
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1026ent and activation of T cells directly activates mTOR
omplex, which is also essential for intimal proliferation of
MCs (5). Although pimecrolimus has been shown to
nhibit T-cell activation in vitro and is highly effective when
pplied locally or given systemically for the treatment of
soriasis and other exfoliating skin conditions (6), there is
o doubt in the pig model that the pimecrolimus-eluting
tent had at best a weak effect on retarding intimal growth.
herefore, in man we cannot assume that T-cell activa-
ion—Th1 (IL-2), and Th2 (IL-4, IL-10) and proliferation,
hich is suppressed by pimecrolimus—necessarily plays an
mportant role in restenosis.
It is well-known that sirolimus and everolimus have a
rofound effect on SMC suppression at very low inhibitory
oncentrations (IC)—IC50 (7). Both drugs have been suc-
essfully applied to stent surfaces and have shown minimal
ate loss in clinical trials (8,9). The IC50 of pimecrolimus as
ell as tacrolimus, also a calcineurin inhibitor for smooth
uscle and endothelial cells suppression, are several thou-
and times less effective as compared with sirolimus (6).
Pimecrolimus, when applied on stents as reported by
rmiston et al. (1), is not effective in preventing the in-stent
eointimal growth but in fact seemed to have stimulated
MC proliferation, with greater late loss as compared with
istoric controls. This result seems counterintuitive at first
lance. Tacrolimus is structurally related to sirolimus. The
KBP12 is the intracellular ligand of both FK506 and
irolimus. The interaction between FKBP12 and FK506
esults in a complex that inhibits calcineurin phosphatase,
hich controls lymphocytic activation, whereas the binding
f FKBP12 to sirolimus produces a complex that inhibits
utophosphorylation of the mTOR kinase and its down-
tream effectors that control SMC proliferation (10,11). A
otential answer for the pro-proliferative characteristics of
imecrolimus can be found in the work of Giordano et al.
10) who recently demonstrated that the immunosuppres-
ant FK506 or “tacrolimus” acts as a growth factor for
ascular SMCs by activating transforming growth factor-
ignaling in SMCs. This finding along with the clinical data
eported by Ormiston et al. (1) emphasizes the importance
f understanding thoroughly the complexity of biologic
ffects of newer pharmacologic agents before their use in
rug delivery devices.
Although the porcine coronary model failed to predict
he phenomenon of excessive neointimal formation after
imecrolimus-eluting stents, we believe animal models still
old predictive value in most cases, because the sequence of
iological events associated with arterial repair are remark-
bly comparable in animals and man (12). For instance,
re-clinical data of the Actinomycin D-eluting stent
howed media necrosis and varying degree of acute inflam-
ation at 28 days and a thick neointima with adventitial
brosis at 90 days (13). These data also predicted the results
een in the clinical ACTION (Actinomycin-Eluting Stent Improves Outcomes by Reducing Neointimal Hyperplasia)
rial, which was interrupted prematurely because of a high
ncidence of repeat target vessel revascularization. In fact,
e also learned the dose-dependent effects of paclitaxel that
esult in tissue necrosis and inflammation in the porcine
nimal model (14). Long-term data in the porcine model
ith a sirolimus-eluting stent (Cypher) demonstrated lack
f efficacy at 90 and 180 days but showed a greater degree of
nflammation with significant eosinophilic infiltration (15),
hich suggested that cases of polymer-induced hypersensi-
ivity might also be seen in man.
Finally, the results with pimecrolimus are consistent with
he findings of multiple clinical studies using stents that elute
imecrolimus. The GENESIS (Randomized, Multicenter
tudy of the Pimecrolimus-Eluting and Pimecrolimus/
aclitaxel-Eluting Coronary Stent System in Patients with
e Novo Lesions of the Native Coronary Arteries) trial was
he first large clinical trial of pimecrolimus-eluting stents in
bioerodable polymer, which also tested dual releasing
imecrolimus- and paclitaxel-eluting stents as well as only a
aclitaxel-eluting stent in man. The enrollment of the
ENESIS trial was suspended early, due to an increase in
arget vessel revascularization in the pimecrolimus-eluting-
tent group (35.5%) (16). The efficacy of the drug-eluting stent
as only observed in patients receiving paclitaxel stents (2%),
nd those receiving pimecrolimus- and paclitaxel-eluting stents
as in between (14.4%). Both the GENESIS and First-In-
an phase I clinical trials with the pimecrolimus-eluting
tent lacked BMS control groups; the usage of a different
olymer in the 2 trials makes it impossible to implicate
imecrolimus as the culprit for the induction of increased
ate loss as compared with historical control BMS.
In conclusion, although the results of this work involving
imecrolimus to prevent restenosis were unsuccessful in
an, they help us to understand the limitations of our
odels as well as the processes that are important in
eointimal proliferation. It seems clear that strategies aimed
t reducing inflammation alone need to be re-evaluated,
hile antiproliferative drugs targeting inhibition of smooth
uscle cell proliferation pathways (i.e., mTOR) warrant
urther consideration as newer agents are developed that will
mpact the future of stent design.
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